Eroxon^® FAQs

Eroxon^®, our lead product was developed specifically for the treatment of erectile dysfunction (“ED”). As a fast-acting, topical treatment available over the counter, Eroxon^® can be used in the moment and integrated into intimacy, including as part of foreplay. This enables a more natural, less medical experience that supports both partners. Positioned as a first-step, particularly for men with mild to moderate or occasional ED, Eroxon^® occupies a distinct space in the category - bridging efficacy, spontaneity, and a more experience-led approach to sexual health.

Eroxon^® is a topical gel applied directly to the head (glans) of the penis for the treatment of ED.

Eroxon^® works through a unique evaporative mode of action. Eroxon^®’s combination of volatile components creates a novel cooling and recovery warming action that stimulates nerve sensors in the highly innervated glans penis, rapidly leading to smooth muscle relaxation, tumescence and erection.

The efficacy of Eroxon^® has been demonstrated in two Phase 3 trials in 300 men with mild, moderate, and severe ED, which investigated improvement in their erectile function compared with baseline. Our commercial partners have also independently conducted four “home-use” studies with over 600 users to validate the strength of the proposition. This has confirmed results that are aligned with the Eroxon^® clinical efficacy data (>60% success rate) providing real world evidence.

In March 2026 we completed a Home User Test (“HUT”) conducted on the current Eroxon^® product and new product Eroxon^® Intense, amongst 223 men under 60 years of age with mostly mild to moderate ED. The results of the HUT were positive with both Eroxon^® and Eroxon^® Intense shown to have high efficacy rates. Subjects in this HUT stated that they were satisfied with the hardness of their erection in 70% and 71% of their sexual encounters using Eroxon^® or Eroxon^® Intense, respectively, and also recorded that their erections lasted long enough to have sexual intercourse in 84% and 85% of encounters, respectively, with efficacy increasing when the product is applied by the partner. The study confirmed the sensorial enhancement of Eroxon^® Intense over Eroxon^® with statistically significant greater intensity during the first two minutes after application.

Reported side effects of Eroxon^® in the trials were minimal: 3% of men reported a headache, significantly fewer than associated with the PDE5i’s,  1% of men reported a ‘localised burning sensation’ and 1.3% of partners reported a headache.

Eroxon^® is for use in men who experience ED. It should not be used by those who do not have problems with ED.

No, Eroxon^® is the first clinically proven topical therapy for erectile dysfunction that can be bought in the UK without the need for a prescription, and is available in many pharmacy and retail stores across the UK..

As well as being available without a doctor’s prescription (‘over the counter’), Eroxon®, is also available on prescription in England and Wales for the treatment of erectile dysfunction since 2024.

Eroxon^® is also available online and in retailers across a number of countries in Europe and the rest of the world.

The definition of a medical device includes products which are used in the treatment of illness or disease but which do not achieve their principal intended action on the human body by pharmacological, immunological or metabolic means. Medical devices are subject to stringent regulations to establish safety and effectiveness.

Approval of Eroxon^® as a medical device clinically proven to treat erectile dysfunction has been granted in both the USA and EU as well as a growing number of other countries across the world.

Eroxon^® is available to purchase online and in retail stores across a growing number of markets across the world.  Further details can be found online at www.eroxon.com.

Eroxon^® is  available to purchase from leading retailers in the USA following the launch in 2024.

www.eroxon.us

Eroxon^® has been granted marketing authorisation in many countries across the world.

Futura has signed commercial deals across the world covering Europe, the USA, Central and South America and the Middle East.

Eroxon^® is now available to men with ED and their partners in 27 countries worldwide, including in the USA, Mexico, throughout most of Europe and a number of countries in the Middle East. We are actively exploring opportunities to expand into the Asia-Pacific region where considerable interest has been expressed by potential commercial partners.

For a list of countries where the product has launched, click here

All distribution will be handled by our appointed distribution partners and retailers.  Eroxon^® addresses the significant and specific medical needs of men who suffer from erectile dysfunction and its use, where approved to be a treatment without the need for a doctor’s prescription, will require careful consideration by the patient in terms of self-diagnosis and use according to product label information.

As most patients who have had a radical prostatectomy suffer from severe ED we would not recommend use of Eroxon^® in this group.

If you have a medical condition you may need to speak to a doctor to discuss your condition to see if the product is suitable for you to use.

Eroxon^® is accompanied by a leaflet, containing warnings and precautions and recommending users have a check-up with their doctor as soon as possible within the first 6 months of using Eroxon^® to ensure that their erection problems are not caused by another serious health condition.

We have not conducted studies on Eroxon^® in combination with PDE5i’s. It is likely that a post-approval study will be needed to demonstrate synergy. We do not anticipate any safety issues in combining the two treatments.

We have a shelf life of 3 years.

It is currently being sold in the UK in Boots for £24.99 for 4 single use applications. Pricing may vary by country and commercial partner and is the responsibility of the commercial partner.